NASDAQ · NEUP
Healthcare · Medical - Pharmaceuticals
$3.81
Up+$0.05 (+1.31%)
Updated Aug 13, 2026, 6:11 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
NEUP closed at $3.81 after 21 trading sessions, up 8.24% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $3.79 | $3.87 | $3.75 | $3.81 | 33.77K |
| Aug 11, 2026 | $3.81 | $3.86 | $3.80 | $3.81 | 30.36K |
| Aug 10, 2026 | $3.81 | $3.89 | $3.81 | $3.86 | 15.5K |
| Aug 7, 2026 | $3.88 | $3.98 | $3.82 | $3.82 | 9.55K |
| Aug 6, 2026 | $3.92 | $4.10 | $3.83 | $3.90 | 29.71K |
| Aug 5, 2026 | $3.89 | $3.99 | $3.84 | $3.95 | 40.9K |
| Aug 4, 2026 | $3.89 | $3.98 | $3.88 | $3.89 | 42K |
| Aug 3, 2026 | $3.86 | $4.05 | $3.75 | $3.93 | 57.87K |
| Jul 31, 2026 | $3.90 | $4.00 | $3.8715 | $3.88 | 37.28K |
| Jul 30, 2026 | $3.80 | $4.06 | $3.73 | $3.92 | 71.16K |
| Jul 29, 2026 | $3.85 | $3.92 | $3.77 | $3.80 | 81.18K |
| Jul 28, 2026 | $3.88 | $3.91 | $3.71 | $3.81 | 97.14K |
| Jul 27, 2026 | $3.73 | $4.0205 | $3.60 | $3.85 | 205.85K |
| Jul 24, 2026 | $3.86 | $3.90 | $3.54 | $3.64 | 392.79K |
| Jul 23, 2026 | $3.80 | $4.20 | $3.68 | $3.92 | 7.62M |
| Jul 22, 2026 | $3.39 | $3.42 | $3.28 | $3.33 | 47.41K |
| Jul 21, 2026 | $3.39 | $3.55 | $3.31 | $3.34 | 47.26K |
| Jul 20, 2026 | $3.40 | $3.485 | $3.30 | $3.30 | 71.08K |
| Jul 17, 2026 | $3.45 | $3.62 | $3.385 | $3.415 | 46.84K |
| Jul 16, 2026 | $3.49 | $3.65 | $3.49 | $3.53 | 16.27K |
| Jul 15, 2026 | $3.55 | $3.62 | $3.45 | $3.52 | 14.63K |
The latest Smart Investors Daily articles mentioning NEUP.
NEUP research
Company profile and research snapshot.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 15, 2026 | HC Wainwright & Co. | Neutral | — |
| Dec 5, 2025 | HC Wainwright & Co. | Buy | — |
| Sep 11, 2025 | Maxim Group | Buy | — |
| Aug 26, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 4, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 23, 2026
Scancell Holdings plc (AIM: SCLP) ("Scancell") and Neuphoria Therapeutics Inc. (NASDAQ:NEUP) ("Neuphoria") today announce an all-share merger in which Scancell will acquire Neuphoria. Upon completion of
Benzinga · Jun 26, 2026
Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected
globenewswire.com · Dec 8, 2025
Company Urges Shareholders to Follow ISS' Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the WHITE proxy card FOR BOTH of the Company's director nominees – Peter Miles Davies and David Wilson.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NEUP.
No results
No recent SID articles mention NEUP.
